Finoriq research workspace

AYTU BIOPHARMA, INC (AYTU) Company Overview

AYTU BIOPHARMA, INC offers prescription products for the treatment of attention deficit hyperactivity. Review AYTU filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Company

AYTU BIOPHARMA, INC (AYTU)

Ticker

AYTU

Market Cap

$23.4M

Latest Price

$2.18

Industry

Biotech & Pharma

Open insider transactions

AYTU BIOPHARMA, INC (AYTU) Current Valuation Metrics

Static valuation preview for AYTU BIOPHARMA, INC (AYTU). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.